Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 2
2008 2
2009 1
2010 2
2011 7
2012 4
2013 1
2015 1
2017 1
2018 1
2023 0

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Acute myeloid leukemia unlikely related to trabectedin treatment.
Cartoafa M, Kahatt C, Soto-Matos A, Roy E, Lardelli P. Cartoafa M, et al. Among authors: soto matos a. Acta Haematol. 2011;126(4):238-9; author reply 240. doi: 10.1159/000330952. Epub 2011 Sep 24. Acta Haematol. 2011. PMID: 21952689 No abstract available.
Population pharmacokinetics of kahalalide F in advanced cancer patients.
Miguel-Lillo B, Valenzuela B, Peris-Ribera JE, Soto-Matos A, Pérez-Ruixo JJ. Miguel-Lillo B, et al. Among authors: soto matos a. Cancer Chemother Pharmacol. 2015 Aug;76(2):365-74. doi: 10.1007/s00280-015-2800-1. Epub 2015 Jun 21. Cancer Chemother Pharmacol. 2015. PMID: 26093949
Population pharmacokinetics of PM00104 (Zalypsis(®)) in cancer patients.
Pérez-Ruixo C, Valenzuela B, Fernández Teruel C, González-Sales M, Miguel-Lillo B, Soto-Matos A, Pérez-Ruixo JJ. Pérez-Ruixo C, et al. Among authors: soto matos a. Cancer Chemother Pharmacol. 2012 Jan;69(1):15-24. doi: 10.1007/s00280-011-1644-6. Epub 2011 May 18. Cancer Chemother Pharmacol. 2012. PMID: 21590449 Clinical Trial.
Plitidepsin has a safe cardiac profile: a comprehensive analysis.
Soto-Matos A, Szyldergemajn S, Extremera S, Miguel-Lillo B, Alfaro V, Coronado C, Lardelli P, Roy E, Corrado CS, Kahatt C. Soto-Matos A, et al. Mar Drugs. 2011;9(6):1007-1023. doi: 10.3390/md9061007. Epub 2011 Jun 9. Mar Drugs. 2011. PMID: 21747745 Free PMC article. Clinical Trial.
Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy.
Cruz C, Llop-Guevara A, Garber JE, Arun BK, Pérez Fidalgo JA, Lluch A, Telli ML, Fernández C, Kahatt C, Galmarini CM, Soto-Matos A, Alfaro V, Pérez de la Haza A, Domchek SM, Antolin S, Vahdat L, Tung NM, Lopez R, Arribas J, Vivancos A, Baselga J, Serra V, Balmaña J, Isakoff SJ. Cruz C, et al. Among authors: soto matos a. J Clin Oncol. 2018 Nov 1;36(31):3134-3143. doi: 10.1200/JCO.2018.78.6558. Epub 2018 Sep 21. J Clin Oncol. 2018. PMID: 30240327 Free PMC article. Clinical Trial.
Trabectedin has a low cardiac risk profile: a comprehensive cardiac safety analysis.
Lebedinsky C, Gómez J, Park YC, Nieto A, Soto-Matos A, Parekh T, Alfaro V, Roy E, Lardelli P, Kahatt C. Lebedinsky C, et al. Among authors: soto matos a. Cancer Chemother Pharmacol. 2011 Nov;68(5):1223-31. doi: 10.1007/s00280-011-1614-z. Epub 2011 Mar 18. Cancer Chemother Pharmacol. 2011. PMID: 21416137 Clinical Trial.
A comprehensive safety analysis confirms rhabdomyolysis as an uncommon adverse reaction in patients treated with trabectedin.
Grosso F, D'Incalci M, Cartoafa M, Nieto A, Fernández-Teruel C, Alfaro V, Lardelli P, Roy E, Gómez J, Kahatt C, Soto-Matos A, Judson I. Grosso F, et al. Among authors: soto matos a. Cancer Chemother Pharmacol. 2012 Jun;69(6):1557-65. doi: 10.1007/s00280-012-1864-4. Epub 2012 Apr 7. Cancer Chemother Pharmacol. 2012. PMID: 22484722 Free PMC article.
17 results